Abstract
Background: We conducted a phase II study of topotecan (Tp) with cisplatin (CDDP) in previously untreated Japanese patients with extensive-disease small cell lung cancer (ED-SCLC). Patients and Methods: In stage 1, a total of 30 patients were allocated to Tp 0.65 mg/m 2 with CDDP 60 mg/m 2 day 1 or Tp 1.00 mg/m 2 with CDDP day 5 following prophylactic granulocyte colony stimulating factor (G-CSF) from day 6. In stage 2, the selective combination in 29 patients was evaluated for response rate, toxicity and overall survival. Results: In stage 1, Tp 1.00 mg/m 2 with CDDP day 5 was selected this schedule had a better hematological profile. In stage 2, the response rate was 83%, and grade 3/4 adverse events were hematological-toxicities. The median survival time was 17.5 months and the 1 year survival rate was 79%. Conclusion: Combination of Tp and CDDP on day 5 with G-CSF support is safe and effective for previously untreated ED-SCLC Japanese patients.
| Original language | English |
|---|---|
| Pages (from-to) | 3449-3456 |
| Number of pages | 8 |
| Journal | Anticancer Research |
| Volume | 31 |
| Issue number | 10 |
| Publication status | Published - Oct 2011 |
Fingerprint
Keywords
- Cisplatin
- Small cell lung cancer
- Topotecan
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer. / Hosomi, Yukio; Shibuya, Masahiko; Niho, Seiji; Ichinose, Yukito; Kiura, Katsuyuki; Sakai, Hiroshi; Takeda, Koji; Kudo, Shinzo; Eguchi, Kenji; Matsui, Kaoru; Masuda, Noriyuki; Ando, Masahiro; Watanabe, Koshiro.
In: Anticancer Research, Vol. 31, No. 10, 10.2011, p. 3449-3456.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer
AU - Hosomi, Yukio
AU - Shibuya, Masahiko
AU - Niho, Seiji
AU - Ichinose, Yukito
AU - Kiura, Katsuyuki
AU - Sakai, Hiroshi
AU - Takeda, Koji
AU - Kudo, Shinzo
AU - Eguchi, Kenji
AU - Matsui, Kaoru
AU - Masuda, Noriyuki
AU - Ando, Masahiro
AU - Watanabe, Koshiro
PY - 2011/10
Y1 - 2011/10
N2 - Background: We conducted a phase II study of topotecan (Tp) with cisplatin (CDDP) in previously untreated Japanese patients with extensive-disease small cell lung cancer (ED-SCLC). Patients and Methods: In stage 1, a total of 30 patients were allocated to Tp 0.65 mg/m 2 with CDDP 60 mg/m 2 day 1 or Tp 1.00 mg/m 2 with CDDP day 5 following prophylactic granulocyte colony stimulating factor (G-CSF) from day 6. In stage 2, the selective combination in 29 patients was evaluated for response rate, toxicity and overall survival. Results: In stage 1, Tp 1.00 mg/m 2 with CDDP day 5 was selected this schedule had a better hematological profile. In stage 2, the response rate was 83%, and grade 3/4 adverse events were hematological-toxicities. The median survival time was 17.5 months and the 1 year survival rate was 79%. Conclusion: Combination of Tp and CDDP on day 5 with G-CSF support is safe and effective for previously untreated ED-SCLC Japanese patients.
AB - Background: We conducted a phase II study of topotecan (Tp) with cisplatin (CDDP) in previously untreated Japanese patients with extensive-disease small cell lung cancer (ED-SCLC). Patients and Methods: In stage 1, a total of 30 patients were allocated to Tp 0.65 mg/m 2 with CDDP 60 mg/m 2 day 1 or Tp 1.00 mg/m 2 with CDDP day 5 following prophylactic granulocyte colony stimulating factor (G-CSF) from day 6. In stage 2, the selective combination in 29 patients was evaluated for response rate, toxicity and overall survival. Results: In stage 1, Tp 1.00 mg/m 2 with CDDP day 5 was selected this schedule had a better hematological profile. In stage 2, the response rate was 83%, and grade 3/4 adverse events were hematological-toxicities. The median survival time was 17.5 months and the 1 year survival rate was 79%. Conclusion: Combination of Tp and CDDP on day 5 with G-CSF support is safe and effective for previously untreated ED-SCLC Japanese patients.
KW - Cisplatin
KW - Small cell lung cancer
KW - Topotecan
UR - http://www.scopus.com/inward/record.url?scp=80054741764&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80054741764&partnerID=8YFLogxK
M3 - Article
C2 - 21965760
AN - SCOPUS:80054741764
VL - 31
SP - 3449
EP - 3456
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 10
ER -